Moderna submits authorisation application for coronavirus vaccine Spikevax XBB.1.5
6 juillet 2023 – Moderna Switzerland GmbH has submitted an application to Swissmedic, the Swiss Agency for Therapeutic Products, for authorisation of its updated monovalent COVID-19 vaccine. It encodes the spike protein for Omicron subvariant XBB.1.5 of SARS-CoV-2. Swissmedic is examining the application.
For more information, see here.